TABA: Tools for the site-specific labeling and immobilization of antibodies for immunoassays

TABA：用于免疫测定的抗体位点特异性标记和固定化工具

• 批准号: 10408659
• 负责人: Feifan Yu
• 金额: $ 5万
• 依托单位: ALPHATHERA, INC.
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-20 至 2022-08-09
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10408659
• 关键词: Antibodies; Categories; Country; Development; Funding; Funding Agency; Goals; Grant; Immobilization; Immunoassay; Label; Marketing; Phase; Sales; Site; Small Business Innovation Research Grant; United States National Institutes of Health; commercialization; interest; success; tool

Summary: AlphaThera continues to scale commercialization of its site-specific antibody conjugation products and has encountered welcoming signs of consumer interest across the US and the world, with sales in several countries and continued customer inquiries. However, increasing expenses associated with scaling and commercialization have led us to explore additional sources of funds. The TABA funds offered by the NIH/SBIR to support Phase I/Phase II grants are an ideal source of funding to enable AlphaThera to continue on its fast-track towards scaled commercialization success. TABA funding will be allocated toward three major categories in support of our commercialization: Multi-channel marketing; Strategic partner development and IP protection.

摘要：AlphaThera继续扩大其位点特异性抗体缀合产品的商业化规模， 欢迎美国和世界各地的消费者感兴趣的迹象，在几个国家的销售和持续的客户查询。 然而，与规模化和商业化相关的费用不断增加，导致我们探索额外的资金来源。的 由NIH/SBIR提供的TABA基金支持第一阶段/第二阶段赠款，是AlphaThera实现以下目标的理想资金来源： 继续快速迈向规模化商业化成功。TABA资金将分配给三个主要类别， 支持我们的商业化：多渠道营销;战略合作伙伴开发和知识产权保护。

项目成果

Labeling of Phospho-Specific Antibodies with oYo-Link® Epitope Tags for Multiplex Immunostaining.

使用 oYo-Link® 表位标签标记磷酸化特异性抗体，用于多重免疫染色。

• DOI: 10.1007/978-1-0716-2811-9_7
• 发表时间: 2023
• 期刊: Methods in molecular biology (Clifton, N.J.)
• 作者: Niu,Jingwen;Hagen,Jodi;Yu,Feifan;Kalyuzhny,AlexanderE;Tsourkas,Andrew
• 通讯作者: Tsourkas,Andrew